Biodegradable microspheres come into sight: A promising biomaterial for delivering drug to the posterior segment of the eyeball
Source abstract
Abstract
Posterior segment disease acts as a major cause of irreversible visual impairments. Successful treatment of posterior segment disease requires the efficient delivery of therapeutic substances to the targeted lesion. However, the complex ocular architecture makes the bioavailability of topically applied drugs extremely low. Invasive delivery approaches like intravitreal injection may cause adverse complications. To enhance the efficiency, several biomedical engineering systems have been developed to increase the penetration efficiency and improve the bioavailability of drugs at the posterior segments. Advantageously, biodegradable microspheres are found to deliver the therapeutic agents in a controlled fashion. The microspheres prepared from novel biomaterials can realize the prolonged release at the posterior segment with minimum side effects. Moreover, it will be degraded automatically into products that are non-toxic to the human body without the necessity of secondary operation to remove the residual polymer matrix. Additionally, biodegradable microspheres have decent thermoplasticity, adjustable hydrophilicity, controlled crystallinity, and high tensile strength, which make them suitable for intraocular delivery. In this review, we introduce the latest advancements in microsphere production technology and elaborate on the biomaterials that are used to prepare microspheres. We discuss systematically the pharmacological characteristics of biodegradable microspheres and compare their potential advantages and limitations in the treatment of posterior segment diseases. These findings would enrich our knowledge of biodegradable microspheres and cast light into the discovery of effective biomaterials for ocular drug delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ocular Surface and Contact Lens · Corneal Surgery and Treatments · Retinal Diseases and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Advances in ocular drug delivery: emphasis on the posterior segment10.1517/17425247.2014.935338 ↗
2. Biological functions of tear film10.1016/j.exer.2020.108115 ↗
3. Polymer-based carriers for ophthalmic drug delivery10.1016/j.jconrel.2018.06.031 ↗
4. Challenges and strategies for the delivery of biologics to the cornea10.1016/j.jconrel.2021.04.008 ↗
5. Ocular drug delivery barriers-role of nanocarriers in the treatment of anterior segment ocular diseases10.3390/pharmaceutics10010028 ↗
6. Role of P-glycoprotein in restricting propranolol transport in cultured rabbit conjunctival epithelial cell layers10.1023/A:1007508714259 ↗
7. The emerging role of topical ocular drugs to target the posterior eye, OPHTHALMOL
8. Transport barriers in transscleral drug delivery for retinal diseases10.1159/000108117 ↗
9. Effect of choroidal perfusion on ocular tissue distribution after intravitreal or suprachoroidal injection in an arterially perfused ex vivo pig eye model10.1089/jop.2013.0063 ↗
10. Distribution of small molecular weight drugs into the porcine lens: studies on imaging mass spectrometry, partition coefficients, and implications in ocular pharmacokinetics10.1021/acs.molpharmaceut.9b00585 ↗
11. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye10.1111/j.1600-0420.2007.00885.x ↗
12. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina10.1007/s11095-008-9745-6 ↗
13. Ophthalmic drug delivery systems for antibiotherapy-A review10.3390/pharmaceutics10010010 ↗
14. Therapeutic nanoemulsions in ophthalmic drug administration: concept in formulations and characterization techniques for ocular drug delivery10.1016/j.jconrel.2020.10.025 ↗
15. The inner blood-retinal barrier: cellular basis and development10.1016/j.visres.2017.05.009 ↗
16. Mucus-penetrating particles and the role of ocular mucus as a barrier to micro- and nanosuspensions10.1089/jop.2020.0022 ↗
17. Role of membrane transporters and metabolizing enzymes in ocular drug delivery10.2174/1389200215666140926152459 ↗
18. P-Glycoprotein expression in human retinal pigment epithelium cell lines10.1016/j.exer.2005.10.029 ↗
19. P-glycoprotein expression in human retinal pigment epithelium
20. Characterization of oligomeric human half-ABC transporter ATP-binding cassette G210.1074/jbc.M310785200 ↗
21. Implications of melanin binding in ocular drug delivery10.1016/j.addr.2017.12.008 ↗
22. Calculation of drug-melanin binding energy using molecular modeling10.1007/BF01955422 ↗
23. Nanocarriers for the delivery of neuroprotective agents in the treatment of ocular neurodegenerative diseases10.3390/pharmaceutics15030837 ↗
24. Cytochrome P450 structure, function and clinical significance: a review10.2174/1389450118666170125144557 ↗
25. Species differences in drug glucuronidation: humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans10.1016/j.dmpk.2017.10.002 ↗
26. Chitosan–polycaprolactone core–shell microparticles for sustained delivery of bevacizumab10.1021/acs.molpharmaceut.0c00260 ↗
27. Long-acting intraocular Delivery strategies for biological therapy of age-related macular degeneration10.1016/j.jconrel.2019.01.007 ↗
28. Drug delivery to the posterior segment of the eye: biopharmaceutic and pharmacokinetic considerations10.3390/pharmaceutics12030269 ↗
29. Considerations for polymers used in ocular drug delivery
30. Insight on updates in polysaccharides for ocular drug delivery10.1016/j.carbpol.2022.120014 ↗
31. A chitosan-based nanosystem as pneumococcal vaccine delivery platform10.1007/s13346-021-00928-3 ↗
32. The potential of chitosan in ocular drug delivery10.1211/0022357022476 ↗
33. Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries10.1016/j.antiviral.2015.09.013 ↗
34. Chitosan derivatives and their application in biomedicine10.3390/ijms21020487 ↗
35. Ocular nanoparticle toxicity and transfection of the retina and retinal pigment epithelium10.1016/j.nano.2008.06.003 ↗
36. Pectin microspheres as ophthalmic carriers for piroxicam: evaluation in vitro and in vivo in albino rabbits10.1016/S0928-0987(99)00023-8 ↗
37. Current trends in gelatin-based drug delivery systems10.3390/pharmaceutics15051499 ↗
38. Safety and efficacy outcomes of the Xen45 Gel Stent use for refractory glaucoma: a surgery series from surgeon trainees at a tertiary teaching hospital10.1186/s40662-019-0171-0 ↗
39. [The dynamic study of retinoic acid and its alginate sodium microspheres in rabbit eye]
40. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema
41. A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery10.1167/iovs.08-2920 ↗
42. Aliphatic polyesters. I. The degradation of poly(ϵ‐caprolactone)in vivo10.1002/app.1981.070261124 ↗
43. Drug delivery nanoparticles: toxicity comparison in retinal pigment epithelium and retinal vascular endothelial cells10.3109/08820538.2015.1114865 ↗
44. Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology10.1016/j.jconrel.2015.05.279 ↗
45. Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration10.2174/1874364101206010054 ↗
46. Preparation and in vivo evaluation of PCADK/PLGA microspheres for improving stability and efficacy of rhGH10.1016/j.ijpharm.2015.10.003 ↗
47. Improving protein stability and controlling protein release by adding poly (Cyclohexane-1, 4-diyl acetone dimethylene ketal) to PLGA microspheres10.2174/1567201812666150316112635 ↗
48. Poly(lactic-co-glycolic acid) devices: production and applications for sustained protein delivery10.1002/wnan.1516 ↗
49. Microencapsulation of luteinizing hormone-releasing hormone agonist in poly (lactic-co-glycolic acid) microspheres by spray-drying10.1016/j.jconrel.2020.01.023 ↗
50. Optimization of experimental parameters for the production of LMWH-loaded polymeric microspheres
51. Biodegradable polymers for microencapsulation of drugs10.3390/10010146 ↗
52. Microfluidic assisted synthesis of PLGA drug delivery systems10.1039/C8RA08972H ↗
53. Size-controlled and monodisperse enzyme-encapsulated chitosan microspheres developed by the SPG membrane emulsification technique10.1016/j.jcis.2011.12.078 ↗
54. Fabricating biopolymer-inorganic hybrid microspheres for enzyme immobilization: connect membrane emulsification with biomimetic mineralization10.1016/j.partic.2021.07.006 ↗
55. Characterisation and applications of microcapsules obtained by interfacial polycondensation10.3109/02652048.2012.676092 ↗
56. PLGA/PLA-Based long-acting injectable depot microspheres in clinical use: production and characterization overview for protein/peptide delivery10.3390/ijms22168884 ↗
57. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy10.1016/j.msec.2019.03.009 ↗
58. Pharmaceutical applications of supercritical fluid extraction of emulsions for micro-/nanoparticle formation10.3390/pharmaceutics13111928 ↗
59. Post-loading of proangiogenic growth factors in PLGA microspheres10.1016/j.ejpb.2020.10.022 ↗
60. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies10.1016/j.preteyeres.2014.04.002 ↗
61. Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study10.1167/iovs.05-1373 ↗
62. Optimisation of aciclovir poly(D,L-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study10.1016/j.ijpharm.2003.12.006 ↗
63. Co-delivery of glial cell-derived neurotrophic factor (GDNF) and tauroursodeoxycholic acid (TUDCA) from PLGA microspheres: potential combination therapy for retinal diseases10.1007/s13346-021-00930-9 ↗
64. Biodegradable additives modulate ganciclovir release rate from PLGA microspheres destined to intraocular administration
65. Vitamin A palmitate and aciclovir biodegradable microspheres for intraocular sustained release10.1016/j.ijpharm.2006.07.010 ↗
66. Retinal ganglion cells survival in a glaucoma model by GDNF/Vit E PLGA microspheres prepared according to a novel microencapsulation procedure10.1016/j.jconrel.2011.06.023 ↗
67. Dexamethasone PLGA microspheres for sub-tenon administration: influence of sterilization and tolerance studies10.3390/pharmaceutics13020228 ↗
68. Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology10.1016/j.jconrel.2015.05.279 ↗
69. Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone10.1016/j.exer.2009.03.012 ↗
70. Inhalable nano-dimpled microspheres containing budesonide-PLGA for improved aerodynamic performance10.2147/IJN.S372582 ↗
71. Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process10.1023/A:1026464124412 ↗
72. Core/shell PLGA microspheres with controllable in vivo release profile via rational core phase design10.1080/21691401.2018.1443940 ↗
73. Influence of processing on the stability and release properties of biodegradable microspheres containing thioridazine hydrochloride10.1016/S0939-6411(97)00126-4 ↗
74. Development of biodegradable controlled release scleral systems of triamcinolone acetonide10.3109/02713683.2010.497599 ↗
75. Ionotropic cross-linked chitosan microspheres for controlled release of ampicillin10.1016/j.ijpharm.2006.01.043 ↗
76. Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development10.3390/pharmaceutics14030614 ↗
77. Microencapsulation of protein drugs for drug delivery: strategy, preparation, and applications10.1016/j.jconrel.2014.09.003 ↗
78. Structured microparticles with tailored properties produced by membrane emulsification10.1016/j.cis.2015.07.013 ↗
79. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application10.1080/10717544.2021.1938756 ↗
80. Porous biodegradable microparticles for delivery of pentamidine10.1016/S0939-6411(01)00150-3 ↗
81. Elimination of residual solvent from PLGA microspheres containing risperidone using supercritical carbon dioxide
82. Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin10.1016/j.actbio.2014.04.024 ↗
83. Factors influencing the diffusion-controlled release of papaverine from poly (L-lactic acid) matrix10.1016/S0168-3659(98)00076-5 ↗
84. Effect of polymer/basic drug interactions on the two-stage diffusion-controlled release from a poly(L-lactic acid) matrix10.1016/S0168-3659(99)00149-2 ↗
85. Coagulation of charged microparticles in neutral gas and charge-induced gel transitions10.1103/PhysRevLett.89.195502 ↗
86. Dual cross-linked chitosan microspheres formulated with spray-drying technique for the sustained release of levofloxacin10.1080/03639045.2019.1569025 ↗
87. PEG–PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells10.1016/j.biomaterials.2010.01.031 ↗
88. Microspheres of biodegradable polymers as a drug-delivery system in the vitreous
89. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations10.1080/10717544.2017.1422296 ↗
90. First order release rate from porous PLA microspheres with limited exit holes on the exterior surface10.1016/S0168-3659(99)00255-2 ↗
91. Seeing is believing, PLGA microsphere degradation revealed in PLGA microsphere/PVA hydrogel composites10.1016/j.jconrel.2016.03.011 ↗
92. Elevated temperature accelerated release testing of PLGA microspheres10.1016/j.jconrel.2006.02.015 ↗
93. Effect of acidic pH on PLGA microsphere degradation and release10.1016/j.jconrel.2007.05.034 ↗
94. An overview of preparation and evaluation sustained-release injectable microspheres10.3109/02652048.2012.742158 ↗
95. Tolerance of high and low amounts of PLGA microspheres loaded with mineralocorticoid receptor antagonist in retinal target site10.1016/j.jconrel.2017.09.029 ↗
96. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage10.1167/iovs.05-0531 ↗
97. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression10.1167/iovs.02-0791 ↗
98. Intravitreal injection of proinsulin-loaded microspheres delays photoreceptor cell death and vision loss in the rd10 mouse model of retinitis pigmentosa10.1167/iovs.16-19300 ↗
99. Controlled delivery of tauroursodeoxycholic acid from biodegradable microspheres slows retinal degeneration and vision loss in P23H rats10.1371/journal.pone.0177998 ↗
100. Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse